Stat news has Rebecca Robins right there at CTAD. I made sure on Twitter she knew about the BETonMACE results. It's kind of hard to miss, since this is the type of conference where there is no concurrent sessions. One presentation room, one presenation at a time. The Symposium 3 "Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies" starts at 5:00 pm MT (4 PM PT, 6 PM CT, 7 PM ET). The next session starts 45 minutes later. BETonMACE cognition sub-study is the last presentation of Symposium 3. So the action starts in 3 hours and will be wrapped up in 4 hours.  

Introduction by chairman Dr. Bengt Winblad, Karolinska Institutet, Sweden.

• Dementias, who and how to treat and by what specialty. Addressing problem and current and potential future therapeutic practices: Dr. Charles DeCarli, UC Davis, USA

• Fluid biomarkers that predict and project brain health: Dr. Henrik Zetterberg, University of Gothenburg, Sweden

• The epigenetic inhibitor Apabetalone corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease: Dr. Ewelina Kulikowski, Resverlogix Corporation, Canada

• Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease: Dr. Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, USA